KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
27 February 2023 - 10:30PM
Business Wire
– Orally disintegrating tablet formulation
shows similar pharmacokinetics to current film-coated tablets
supporting lifecycle extension in US and EU -
– Real-word evidence and patient survey data
demonstrate treatment burden associated with the administration of
injectable on-demand treatments in HAE -
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of oral, small molecule protease inhibitors,
today presented five posters at the American Academy of Allergy,
Asthma & Immunology (AAAAI) Annual Meeting in San Antonio,
Texas.
The following presentations occurred at the 2023 AAAAI Annual
Meeting:
- A comparative bioavailability of sebetralstat following
administration of orally disintegrating tablets and film-coated
tablets in healthy volunteers: Michael D. Smith, KalVista
Pharmaceuticals Inc., Cambridge, MA, USA
- Reporting of Adverse Drug Reactions with Parenteral Drugs
for the On-Demand Treatment of Hereditary Angioedema Attacks –
Analysis of the FAERS Database 2009 to 2022: Dr. Raffi
Tachdjian, UCLA School of Medicine, Los Angeles, CA, USA
- Anxiety Associated With Parenteral On-Demand Treatment For
Hereditary Angioedema (HAE): Dr. Autumn Burnette, Division of
Allergy and Immunology, Howard University Hospital, Washington, DC,
USA
- Patient Perspectives On Early Use Of On-Demand Treatment For
Hereditary Angioedema (HAE) Attacks to Reduce Severity and
Duration: Dr. Cristine Radojicic, Division of Pulmonary,
Allergy and Critical Care, Duke University Medical Center, Durham,
North Carolina, USA
- Treatment with Sebetralstat Reduces the Cumulative Symptom
Severity of Hereditary Angioedema Attacks in a Phase 2 Trial:
Dr. Jonathan A. Bernstein, University of Cincinnati College of
Medicine and Bernstein Clinical Research Center, LLC, Cincinnati,
OH, USA
“The real-world data presented at AAAAI highlight the
significant treatment burden and anxiety associated with existing
injectable on-demand therapies, and the potential for sebetralstat,
an investigational oral plasma kallikrein inhibitor, to improve the
treatment experience for people living with HAE,” said Andrew
Crockett, Chief Executive Officer of KalVista. “Additionally
highlighting this potential are the data from our phase 2 trial
assessing sebetralstat for on-demand of HAE attacks demonstrating
that early treatment decreased cumulative attack and symptom
severity compared to placebo, as well as new data supporting
continued advancement of our orally disintegrating tablet
formulation.”
Links to all posters and presentations can be found on the
KalVista website under “Publications”.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista is developing sebetralstat as an
oral on-demand therapy for HAE attacks and is enrolling the Phase 3
KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa
inhibitor program represents a new generation of therapies that may
further improve the treatment for people living with HAE and other
diseases.
For more information about KalVista, please visit
www.kalvista.com.
For more information on the sebetralstat HAE on-demand Phase 3
KONFIDENT study, please visit www.konfidentstudy.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and its results, our ability to commence clinical
studies or complete ongoing clinical studies, including our Phase 3
KONFIDENT trial, and to obtain regulatory approvals for
sebetralstat and other candidates in development, the success of
any efforts to commercialize sebetralstat, the ability of
sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2022, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230227005338/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Mar 2024 to Apr 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2023 to Apr 2024